IP Library Granted Patent US 9,302,005
Granted Patent B2
US 9,302,005 · App. 14/192,376 · Granted Apr 5, 2016

Methods and materials for treating cancer

Inventors: Haidong Dong (Rochester, MN); Eugene D. Kwon (Rochester, MN); Svetomir N. Markovic (Rochester, MN); Christopher J. Krco (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
A61K45/00C07K14/70532A61K35/17
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,302,005
App. No.
14/192,376
Granted
Apr 5, 2016
Kind
B2
Abstract

This document provides methods and materials involved in treating cancer. For example, methods and materials for identifying a mammal as having an elevated level of PD-1 + /CD11a high CD8 T cells having the potential to exert anti-cancer effects are provided. In addition, methods and materials for identifying a mammal as having an elevated level of PD-1 + /CD11a high CD8 T cells and administering a PD-1 inhibitor to such a mammal are provided.

Claims (9)

1. A method for treating a mammal having cancer, wherein said method comprises:

(a) identifying said mammal as having an elevated level of PD-1 + /CD11a high CD8 T cells within a blood, body fluid, or tumor samplerelative to a reference level of PD-1 30 /CD11a high CD8 T cells in mammals without cancer, and

(b) administering a PD-1 inhibitor to said mammal, wherein naturally-occurring tumor-reactive CD8 CTLs within a PD-1 + /CD11a high CD8 T cell population of said mammal exert an anti-cancer effect against said cancer.

2. The method of claim 1 , wherein said mammal is a human.

3. The method of claim 1 , wherein said elevated level is determined using flow cytometry.

4. The method of claim 1 , wherein said cancer is a melanoma cancer, a breast cancer, a lung cancer, a renal cell carcinoma cancer, a pancreas cancer, a prostate cancer, a colon cancer, a brain cancer, a liver cancer, or an ovarian cancer.

5. A method for treating cancer, wherein said method comprises administering a PD-1 inhibitor to a mammal identified as having an elevated level of PD-1 + /CD11a high CD8 T cells within a blood, body fluid, or tumor sample relative to a reference level of PD-1 30 /CD11a high CD8 T cells in mammals without cancer, wherein naturally-occurring tumor-reactive CD8 CTLs within a PD-1 + /CD11a high CD8 T cell population of said mammal exert an anti-cancer effect against said cancer.

6. The method of claim 5 , wherein said mammal is a human.

7. The method of claim 5 , wherein said cancer is a melanoma cancer, a breast cancer, a lung cancer, a renal cell carcinoma cancer, a pancreas cancer, a prostate cancer, a colon cancer, a brain cancer, a liver cancer, or an ovarian cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2014
From: DONG, HAIDONG; KWON, EUGENE D.; MARKOVIC, SVETOMIR N.; KRCO, CHRISTOPHER J.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 032730/0737 →
Continuity (2)
Provisional Application 61786199 · Mar 14, 2013
Related Publication 20140271674A1 · Sep 18, 2014